Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 500-502

  Helsing, M D ^a  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

non Hodgkin's lymphoma; trofosfamide

Indexed keywords

TROFOSFAMIDE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031105635     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89029-6     Document Type: Article

References (6)

1. Boos J, Küpker F, Blaschke G, Jürgens H. Trofosfamide metabolism in different species - ifosfamide is the predominant metabolite. Cancer Chemother Pharmacol. 33:1993;71-76.
2. Potzi P, Kühböck J, Aiginger P. Ixoten maintenance therapy in solid tumours and malignant lymphomas. Proceedings of the 13th International Congress of Chemotherapy 1983, Vienna. 210:August 28-September 2, 1993;21-26.
3. Falkson G, Falkson HC. Trofosfamide in the treatment of patients with cancer. S Afr Med J. 53:1978;886-888.
4. Wist E, Risberg T. Trofosfamide in non-Hodgkin's lymphoma. Acta Oncol. 7:1991;819-821.
5. Salminen E, Nikkanen V, Lindholm L. Trofosfamide is effective in refractory non-Hodgkin's lymphoma. Eur J Cancer. 31A:1995;2419-2420.
6. Martinsson U, Carlsson S, Christiansen I, Glimelius B, Hagberg H. Ixoten in non-Hodgkin lymphomas. Abstract P692, 19th Congress of the European Society for Medical Oncology. Lisbon :1994.